Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2016 Financial Results on March 1, 2017

WOODCLIFF LAKE, N.J.--()--Eagle Pharmaceuticals, Inc. ("Eagle" or “the Company”) (Nasdaq: EGRX) announced today that the Company will release its 2016 fourth quarter and full year financial results on Wednesday, March 1, 2017, before the market opens.

Scott Tarriff, Chief Executive Officer, David Pernock, President and Chief Commercial Officer, and David E. Riggs, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date       Wednesday, March 1, 2017
Time 8:30 A.M. EST
Toll free (U.S.) 888-632-3384
International 785-424-1675
Webcast (live and replay)

www.eagleus.com, under the “Investor Relations” section

 

A replay of the conference call will be available for one week after the call's completion by dialing 800-839-1320 (US) or 402-220-0488 (International) and entering conference call ID EGRXQ416. The webcast will be archived for 30 days at the aforementioned URL.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.

Contacts

Investor Relations for Eagle Pharmaceuticals, Inc:
Lisa M. Wilson, 212-452-2793

Contacts

Investor Relations for Eagle Pharmaceuticals, Inc:
Lisa M. Wilson, 212-452-2793